Vanda Pharmaceuticals Inc.
VNDA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $293,778 | $278,452 | $268,642 | $279,295 |
| - Cash | $70,022 | $80,983 | $111,796 | $102,316 |
| + Debt | $6,227 | $11,638 | $11,745 | $12,360 |
| Enterprise Value | $229,983 | $209,107 | $168,591 | $189,339 |
| Revenue | $56,258 | $52,590 | $50,041 | $53,185 |
| % Growth | 7% | 5.1% | -5.9% | – |
| Gross Profit | $53,304 | $48,103 | $46,520 | $50,595 |
| % Margin | 94.7% | 91.5% | 93% | 95.1% |
| EBITDA | -$29,231 | -$32,869 | -$31,115 | -$8,306 |
| % Margin | -52% | -62.5% | -62.2% | -15.6% |
| Net Income | -$22,586 | -$27,207 | -$29,494 | -$4,912 |
| % Margin | -40.1% | -51.7% | -58.9% | -9.2% |
| EPS Diluted | -0.38 | -0.46 | -0.5 | -0.085 |
| % Growth | 17.4% | 8% | -491.7% | – |
| Operating Cash Flow | -$31,626 | -$15,252 | -$33,147 | -$1,817 |
| Capital Expenditures | -$161 | -$299 | -$436 | -$214 |
| Free Cash Flow | -$31,787 | -$15,551 | -$33,583 | -$2,031 |